Meeting
2016 ASCO Annual Meeting
A Phase I/Ib study of MEK162 (binimetinib), a MEK inhibitor, in combination with carboplatin and pemetrexed in patients with non-squamous NSCLC.
Authors
Safiya Karim
University of Saskatchewan, Saskatoon, SK, Canada
Safiya Karim , Ronald Feld , Natasha B. Leighl , Frances A. Shepherd , Penelope Ann Bradbury , Geoffrey Liu , Donna M. Graham
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT02185690
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS2609)
DOI
10.1200/JCO.2016.34.15_suppl.TPS2609
Abstract #
TPS2609
Poster Bd #
300a
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Somatic mutation spectrum of non-small cell lung cancers (NSCLCs) from African Americans (AAs).
First Author: Philip Edward Lammers
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A randomized phase II trial of MEK and CDK4/6 inhibitors vesus tipiracil/trifluridine (TAS-102) in metastatic KRAS/NRAS mutant (mut) colorectal cancer (CRC).
First Author: Michael Sangmin Lee
Poster
2021 ASCO Annual Meeting
Molecular characterization of the Ras-MAPK pathway in metastatic breast cancer.
First Author: Justin Wayne Wong Tiu-lim
Poster
2019 Breakthrough
Mutation spectrum of major cancer driver genes in Vietnamese NSCLC patients.
First Author: Uyen Vu Tran